2024.11.14 MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver MN-001patents
2024.08.29 MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition MN-166patents
2024.06.05 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer MN-166patents
2024.05.20 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer MN-166patents
2024.05.14 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome MN-166patents
2024.05.07 MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast) MN-166patents
2024.03.26 MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan MN-166patents
2024.01.17 MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China MN-166patents
2023.12.06 MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe MN-166Progressive MSpatents
2023.10.10 MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada ALSMN-166patents
2023.08.16 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe MN-166patents
2023.08.15 MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe MN-001patents
2023.08.14 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe MN-001NASH/NAFLDpatents
2023.05.14 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe MN-166patents
2023.04.30 MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada MN-001patents
2023.01.10 MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada MN-001patents
2023.01.09 MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil MN-001patents
2022.03.17 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea MN-001NASH/NAFLDpatents
2022.02.01 MediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Korea MN-001patents
2022.01.31 MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada MN-001patents
2022.01.27 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe AddictionMN-166patents
2022.01.26 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Europe MN-001patents
2021.12.13 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS ALSMN-166patents
2021.07.06 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Ophthalmic Disease MN-166patents
2021.05.06 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe ALSMN-166patents
2021.01.19 MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Japan ALSMN-166patents
2020.12.29 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS MN-166Progressive MSpatents
2020.06.24 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Europe MN-001patents
2020.04.21 MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma GlioblastomaMN-166patents
2020.02.18 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan MN-001NASH/NAFLDpatents
2020.01.28 MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe FibrosisMN-001patents
2019.10.28 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada ALSMN-166patents
2019.10.23 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in Japan MN-001NASH/NAFLDpatents
2019.10.08 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in Japan FibrosisMN-001patents
2019.10.01 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China FibrosisMN-001patents
